multiple myeloma

FDA approves new treatment for multiple myeloma

On Nov. 30, the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received…

Malignancy-induced hypercalcemia

A 69-year-old man arrives in the ED with reports of persistent fatigue, nausea, vomiting, anorexia, excessive thirst, increased urination, and back pain for 3 days. His medications include…

New treatment for multiple myeloma

The U.S. Food and Drug Administration (FDA) recently approved Sanofi-Aventis’ Sarclisa (isatuximab-irfc) for the treatment of  adult patients with multiple myeloma. Isatuximab-irfc was previously designated its orphan drug…

Malignancy-induced hypercalcemia

A 69-year-old man arrives in the ED with reports of persistent fatigue, nausea, vomiting, anorexia, excessive thirst, increased urination, and back pain for 3…

New treatment for multiple myeloma

The U.S. Food and Drug Administration (FDA) recently approved Sanofi-Aventis’ Sarclisa (isatuximab-irfc) for the treatment of  adult patients with multiple myeloma. Isatuximab-irfc was previously…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey

Poll

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.